These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 28161070)

  • 1. Metalloproteinase 11, potential marker and molecular target in advanced and castration-resistant prostate cancer. Culture study of peritumoral fibroblasts.
    Fernandez-Gomez JM; Eiro N; García-Rodríguez JJ; Quintás-Blanco A; Gonzalez-Ruiz de León C; Perez de Haro ML; Vizoso-Piñero F
    Actas Urol Esp; 2017; 41(6):376-382. PubMed ID: 28161070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stromal factors involved in human prostate cancer development, progression and castration resistance.
    Eiro N; Fernandez-Gomez J; Sacristán R; Fernandez-Garcia B; Lobo B; Gonzalez-Suarez J; Quintas A; Escaf S; Vizoso FJ
    J Cancer Res Clin Oncol; 2017 Feb; 143(2):351-359. PubMed ID: 27787597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intensity of stromal changes is associated with tumor relapse in clinically advanced prostate cancer after castration therapy.
    Wu JP; Huang WB; Zhou H; Xu LW; Zhao JH; Zhu JG; Su JH; Sun HB
    Asian J Androl; 2014; 16(5):710-4. PubMed ID: 24875819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current management of advanced and castration resistant prostate cancer.
    Gomella LG; Petrylak DP; Shayegan B
    Can J Urol; 2014 Apr; 21(2 Supp 1):1-6. PubMed ID: 24775717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer-associated fibroblasts affect breast cancer cell gene expression, invasion and angiogenesis.
    Eiro N; González L; Martínez-Ordoñez A; Fernandez-Garcia B; González LO; Cid S; Dominguez F; Perez-Fernandez R; Vizoso FJ
    Cell Oncol (Dordr); 2018 Aug; 41(4):369-378. PubMed ID: 29497991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MMP1 and MMP11 Expression in Peripheral Blood Mononuclear Cells upon Their Interaction with Breast Cancer Cells and Fibroblasts.
    Eiro N; Cid S; Aguado N; Fraile M; de Pablo N; Fernández B; Domínguez F; González LO; Vizoso FJ
    Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33396463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated circulating tissue inhibitor of metalloproteinase 1 (TIMP-1) levels are associated with neuroendocrine differentiation in castration resistant prostate cancer.
    Gong Y; Chippada-Venkata UD; Galsky MD; Huang J; Oh WK
    Prostate; 2015 May; 75(6):616-27. PubMed ID: 25560638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current state of castration-resistant prostate cancer.
    Petrylak DP
    Am J Manag Care; 2013 Dec; 19(18 Suppl):s358-65. PubMed ID: 24494690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Both High and Low Serum Total Testosterone Levels Indicate Poor Prognosis in Patients with Prostate Cancer.
    Izumi K; Shigehara K; Nohara T; Narimoto K; Kadono Y; Mizokami A
    Anticancer Res; 2017 Oct; 37(10):5559-5564. PubMed ID: 28982870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Knockdown of MMP11 inhibits proliferation and invasion of gastric cancer cells.
    Kou YB; Zhang SY; Zhao BL; Ding R; Liu H; Li S
    Int J Immunopathol Pharmacol; 2013; 26(2):361-70. PubMed ID: 23755751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation between Microvascular Density and Matrix Metalloproteinase 11 Expression in Prostate Cancer Tissues: a Preliminary Study in Thailand.
    Kanharat N; Tuamsuk P
    Asian Pac J Cancer Prev; 2015; 16(15):6639-43. PubMed ID: 26434888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating Tumor Cells as a Marker for Progression-free Survival in Metastatic Castration-naïve Prostate Cancer.
    Josefsson A; Linder A; Flondell Site D; Canesin G; Stiehm A; Anand A; Bjartell A; Damber JE; Welén K
    Prostate; 2017 Jun; 77(8):849-858. PubMed ID: 28295408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression patterns of candidate susceptibility genes HNF1β and CtBP2 in prostate cancer: association with tumor progression.
    Debiais-Delpech C; Godet J; Pedretti N; Bernard FX; Irani J; Cathelineau X; Cussenot O; Fromont G
    Urol Oncol; 2014 May; 32(4):426-32. PubMed ID: 24332637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reprint of: de novo neuroendocrine features in prostate cancer.
    Abdulfatah E; Fine SW; Lotan TL; Mehra R
    Hum Pathol; 2023 Mar; 133():115-125. PubMed ID: 36894369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of Advanced Prostate Carcinoma - an Interdisciplinary Recommendation].
    Omlin A; Spahn M; Beyer J; Eberli D; Gillessen S; Jochum W; Kueng M; Nitzsche E; Rentsch CA; Roggero E; Schmid HP; Stenner F; Templeton AJ; Wild D; Wyler S; Zwahlen D; Cathomas R
    Praxis (Bern 1994); 2018 Sep; 107(19):1043-1051. PubMed ID: 30227804
    [No Abstract]   [Full Text] [Related]  

  • 16. Advances in systemic therapies for metastatic castration-resistant prostate cancer.
    Pant MK; Abughaban A; Aragon-Ching JB
    Future Oncol; 2014 Nov; 10(14):2213-26. PubMed ID: 25471035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen and prostatic stroma.
    Niu YJ; Ma TX; Zhang J; Xu Y; Han RF; Sun G
    Asian J Androl; 2003 Mar; 5(1):19-26. PubMed ID: 12646998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of store-operated channel components in prostate cancer: the prognostic paradox.
    Perrouin Verbe MA; Bruyere F; Rozet F; Vandier C; Fromont G
    Hum Pathol; 2016 Mar; 49():77-82. PubMed ID: 26826413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of HOXB13 expression patterns in localized and metastatic castration-resistant prostate cancer.
    Patel RA; Sayar E; Coleman I; Roudier MP; Hanratty B; Low JY; Jaiswal N; Ajkunic A; Dumpit R; Ercan C; Salama N; O'Brien VP; Isaacs WB; Epstein JI; De Marzo AM; Trock BJ; Luo J; Brennen WN; Tretiakova M; Vakar-Lopez F; True LD; Goodrich DW; Corey E; Morrissey C; Nelson PS; Hurley PJ; Gulati R; Haffner MC
    J Pathol; 2024 Jan; 262(1):105-120. PubMed ID: 37850574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes of protein expression in prostate cancer having lost its androgen sensitivity.
    Bánfi G; Teleki I; Nyirády P; Keszthelyi A; Romics I; Fintha A; Krenács T; Szende B
    Int Urol Nephrol; 2015 Jul; 47(7):1149-54. PubMed ID: 25953123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.